ClinicalTrials.gg
RecruitingNCT06410495Updated Mar 28, 2025

Digital Dyadic Family Based Intervention to Improve Sleep in Children with ODD and Their Parents: NiteCAPP SINCC (Pilot)

An interventional study of NiteCAPP SINCC in Oppositional Defiant Disorder and Insomnia Chronic, sponsored by University of South Florida. Recruiting at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by University of South Florida · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
8 Years to 17 Years
Sex
All
01

Study summary

In this proposal a brief web-based cognitive behavioral treatment for insomnia (CBT-I) for children with oppositional defiant disorder (ODD) and their parents is iteratively adapted and tested for acceptability, feasibility, and preliminary efficacy.

02

Conditions studied

  • Oppositional Defiant Disorder
  • Insomnia Chronic
03

In context

Oppositional Defiant Disorder

86 studies on the registry are indexed under Oppositional Defiant Disorder; 16 are open to participants now.

This study's planned enrollment of 30 is below the median of 102 across 76 interventional studies indexed under Oppositional Defiant Disorder.

Browse Oppositional Defiant Disorder studies →

Lead sponsor

University of South Florida is the lead sponsor of 340 studies on the registry; 65 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 4 (24%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Child ages 8-17 with ODD (prior diagnosis) and insomnia
  2. Child and parent English proficiency.

Insomnia:

  1. complaints of difficulties falling asleep, staying asleep, or early morning awakening by child report or parent observation for 3+ mos
  2. daytime dysfunction (mood, cognitive, social, academic) due to insomnia
  3. baseline diaries and actigraphy indicate >30 mins. of sleep onset latency, wake after sleep onset, or early morning awakening (time between last awakening and out of bed time) on 6+ nights

Exclusion criteria

Exclusion criteria:

  1. Parent unable to provide or child unable to provide assent
  2. Family unwilling to accept random assignment
  3. Child/parent participation in another randomized research project
  4. Parent unable to complete forms or implement treatment procedures due to cognitive impairment
  5. Child untreated medical comorbidity, including other sleep disorders (e.g., apnea, epilepsy, psychotic disorders, suicidal ideation/intent, [frequent] parasomnias)
  6. Child psychotropic or other medications that alter sleep with the exceptions of stimulants, sleep medications, and/or melatonin
  7. Child participation in non-pharmacological treatment (including CBT) for sleep outside current trial
  8. Parent report of inability to undergo Holter Monitoring or actigraphy (e.g., extreme sensitivity, behavioral outbursts)
  9. Other conditions adversely affecting trial participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    NiteCAPP SINCC

    Content includes both standard CBT-I techniques \[sleep hygiene, stimulus control, sleep restriction, cognitive therapy\] as well as those targeting children with ODD and their parents. Active child participation is a goal but may be limited due to age/abilities. Parents will work with children to implement behavioral strategies.

    Behavioral: NiteCAPP SINCC

Interventions

  • BehavioralNiteCAPP SINCC

    Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.

06

What researchers measure

Primary outcomes

  1. Child Daily Sleep Diaries

    Daily diaries filled out by children with parent assistance that measure sleep efficiency, sleep onset latency, and total sleep time. Diaries also measure child behavior.

    Time frame: Each morning for 14-days at 0 weeks, 6 weeks, and 10 weeks

  2. Parent Daily Sleep Diaries

    Daily diaries filled out by parent that measure sleep efficiency, sleep onset latency, and total sleep time. Diaries also measure child behavior.

    Time frame: Each morning for 14-days at 0 weeks, 6 weeks, and 10 weeks

Secondary outcomes

  1. Child Actigraphy

    Physiological measure of sleep efficiency, sleep onset latency, and total sleep time

    Time frame: 24/7 during the 2 week assessment at 0 weeks, 6 weeks, and 10 weeks

  2. Parent Actigraphy

    Physiological measure of sleep efficiency, sleep onset latency, and total sleep time

    Time frame: 24/7 during the 2 week assessment at 0 weeks, 6 weeks, and 10 weeks

  3. Child Heartrate Variability

    Child heartrate variability will be measured during the following: 1) resting state, 2) cold pressor stimulation to hand (place hand to bottom of 4° Celsius ice water) for 30 secs, 3) 3 min recovery, 4) cold pressor stimulation to other hand for 30secs, 5) resting state

    Time frame: during a cold-pressor task at 0 weeks, 6 weeks, 10 weeks

  4. Parent Heartrate Variability

    Parent heartrate variability will be measured during the following: 1) resting state, 2) cold pressor stimulation to hand (place hand to bottom of 4° Celsius ice water) for 30 secs, 3) 3 min recovery, 4) cold pressor stimulation to other hand for 30secs, 5) resting state

    Time frame: during a cold-pressor task at 0 weeks, 6 weeks, 10 weeks

  5. The Revised Childhood Anxiety and Depression Scale

    Measures child anxiety and depression

    Time frame: 0 weeks, 6 weeks, 10 weeks

  6. PROMIS Child Sleep Disturbance

    Measures child sleep

    Time frame: 0 weeks, 6 weeks, 10 weeks

  7. Alabama Parenting Questionnaire

    Measures parenting behaviors

    Time frame: 0 weeks, 6 weeks, 10 weeks

  8. Perceived Stress Scale

    Measures parent stress

    Time frame: 0 weeks, 6 weeks, 10 weeks

  9. Child Disruptive Behavior Disorders Checklist

    Measures child disruptive behaviors

    Time frame: 0 weeks, 6 weeks, 10 weeks

  10. Beck Depression Inventory-II

    Measures parent depression

    Time frame: 0 weeks, 6 weeks, 10 weeks

  11. State-Trait Anxiety Inventory

    Measures parent anxiety

    Time frame: 0 weeks, 6 weeks, 10 weeks

  12. PROMIS Adult Sleep Disturbance

    Measures parent sleep

    Time frame: 0 weeks, 6 weeks, 10 weeks

  13. Pediatric Sleep Questionnaire

    Measures child sleep apnea risk

    Time frame: 0 weeks, 6 weeks, 10 weeks

  14. Epworth Sleepiness Scale

    Measures parent sleep apnea risk

    Time frame: 0 weeks, 6 weeks, 10 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06410495
Responsible party
Melanie Stearns (Assistant Professor, University of South Florida) — Principal investigator
First posted
May 13, 2024
Start date
May 1, 2024
Primary completion
Aug 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Mar 28, 2025

Study contacts

Melanie Stearns, PhD
Contact
mstearns@usf.edu
8123828872

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion